Anacetrapib
Drug / Medication
Merck's CETP inhibitor which, despite only moderately lowering LDL, confirmed that CETP inhibition reduces heart attacks by lowering LDL, fitting the CTT meta-regression line.
Mentioned in 2 videos
Save the 2 videos on Anacetrapib to your own pod.
Sign up free to keep building your knowledge base on Anacetrapib as more episodes are added.
Videos Mentioning Anacetrapib
255-Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease, familial hypercholesterolemia
Peter Attia MD
Merck's CETP inhibitor which, despite only moderately lowering LDL, confirmed that CETP inhibition reduces heart attacks by lowering LDL, fitting the CTT meta-regression line.
210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.
Peter Attia MD
A CETP inhibitor by Merck that showed a small, though not spectacular, cardiovascular benefit in the REVEAL trial, but drug accumulation in adipose tissue stopped further development.